Connection

DAVID ALLISON to Hypoglycemic Agents

This is a "connection" page, showing publications DAVID ALLISON has written about Hypoglycemic Agents.
Connection Strength

0.872
  1. Neglecting regression to the mean continues to lead to unwarranted conclusions: Letter regarding "The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial". Adv Clin Exp Med. 2019 Nov; 28(11):1569-1570.
    View in: PubMed
    Score: 0.463
  2. Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci. 2010 May; 65(5):468-74.
    View in: PubMed
    Score: 0.238
  3. Unaccounted for regression to the mean renders conclusion of article titled "Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin" unsubstantiated. Diabetes Obes Metab. 2018 08; 20(8):2039-2040.
    View in: PubMed
    Score: 0.104
  4. Calorie restriction: what recent results suggest for the future of ageing research. Eur J Clin Invest. 2010 May; 40(5):440-50.
    View in: PubMed
    Score: 0.060
  5. Prescription medications: a modifiable contributor to obesity. South Med J. 1999 Sep; 92(9):898-904.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.